More recently, another systematic review and meta-analysis estimated irAE in 6331 patients with advanced melanoma treated with anti-CTLA-4 or anti-PD-1 antibodies as monotherapy or in any concomitant or sequential combination [81]. This evidence concerns the gene CTLA4 and melanoma.